Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840103 | 0.86 | EPHX2 (0.36) | EPHX2EPHX1MTNR1AMTNR1B | |
| SCHEMBL2616732 | 0.85 | EPHX1 (0.37) | EPHX1DNM1LMNAACHE | |
| SCHEMBL4417326 | 0.85 | EPHX2 (0.38) | EPHX2MTNR1AMTNR1B | |
| SCHEMBL13840101 | 0.84 | EPHX2 (0.40) | EPHX2DNM1 | |
| SCHEMBL2024703 | 0.81 | CHRNB2 (0.43) | EPHX1LMNAMTNR1AMTNR1BNPC1 | |
| SCHEMBL22522246 | 0.81 | CHRNB2 (0.33) | EPHX2LMNA | |
| SCHEMBL22573784 | 0.80 | ALDH1A1 (0.35) | EPHX2LMNAALDH1A1 | |
| SCHEMBL19929282 | 0.79 | EPHX1 (0.39) | EPHX1LMNAACHEALDH1A1 | |
| SCHEMBL3359618 | 0.78 | EPHX1 (0.45) | EPHX2EPHX1DNM1LMNAACHE | |
| SCHEMBL2565754 | 0.78 | CA14 (0.33) | EPHX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092212-A1 | SELECTIVE ETCH INHIBITOR COMPOUNDS AND RELATED METHODS | ENTEGRIS INC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092212-A1 | SELECTIVE ETCH INHIBITOR COMPOUNDS AND RELATED METHODS | APOL1, ATXN2L, SRSF9 | EPHX2 1624/4885EPHX1 2736/4885DNM1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.